SAREPTA THERAPEUTICS INC (SRPT)

Sarepta Therapeutics to Announce First Quarter 2024 Financial Results

RSI Alert: Sarepta Therapeutics (SRPT) Now Oversold

Noteworthy Thursday Option Activity: SRPT, GFF, ADBE

Why Sarepta's First-Quarter Report Is Already Dead In The Water: Analyst

Sarepta stock has taken a beating this year, and it might not be over with the first-quarter report looming.

2 Biotech Stocks to Buy Hand Over Fist in April

These drugmakers have made important moves over the past year.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

How Sleeper Biotech Solid Biosciences, With A 687% Gain, Is Making A Comeback

The company could follow Sarepta Therapeutics with a gene therapy for Duchenne muscular dystrophy.

Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?

The threat is still emerging, but it could be significant.

Got $1,000? Buy These Hot Growth Stocks Before They Take Off.

These stocks haven't been able to get much traction lately, even though they clearly deserve to now.

Sarepta Therapeutics Stock Has 73% Upside, According to 1 Wall Street Analyst

The upcoming regulatory decision on its latest drug could be big.

Sarepta Therapeutics to Present at Upcoming Investor Conferences

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Noteworthy Thursday Option Activity: NKE, IONQ, SRPT

Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program

Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript

SRPT earnings call for the period ending December 31, 2023.

Sarepta Therapeutics Non-GAAP EPS of $0.82 beats by $0.45, revenue of $396.78M beats by $10.62M (NASDAQ:SRPT)

Sarepta Therapeutics announces impressive Q4 2023 financial results with non-GAAP EPS beating estimates by $0.45 and revenue exceeding expectations by...

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments

Is It Too Late to Buy Sarepta Therapeutics Stock?

The company's hyperfocus on its core area could continue to be highly lucrative.

Sarepta Therapeutics Moves Up In Market Cap Rank, Passing KeyCorp

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results

Notable Friday Option Activity: OMI, SRPT, AAP

Why Sarepta Therapeutics Stock Is Soaring Today

The biotech just scored a big FDA win with an even bigger one potentially coming by June.

Sarepta stock rises as FDA reviews Elevidys label expansion

Sarepta Therapeutics (SRPT) saw a 15% premarket rise after FDA accepted its efficacy supplement for Duchenne drug Elevidys, aiming to expand its label. Read more here.

Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication

2 Magnificent Growth Stocks to Buy With $500

No need to break the bank to invest in promising stocks.